ClinicalTrials.gg
Active, not recruitingNCT06906497ADfindUpdated Sep 15, 2026

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

A Phase 4 interventional study of lebrikizumab in Atopic Dermatitis, sponsored by Johann E Gudjonsson MD PhD. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Johann E Gudjonsson MD PhD · Phase 4, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Planned enrollment
23rd of 24
48 · median 252
Started
2025
with 1 other
Phase 4
4 of 24
2 open now
Registered
20th of 24
by date
Lead sponsor
1 of 24
Johann E Gudjonsson MD PhD

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 23rd largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 20th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

Read the detailed description

Lebrikizumab, the drug used in the study, has been deemed IND exempt by the FDA.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of AD for at least 1 year before the screening visit and topical treatment was inadequate or inadvisable.
  • Moderate-to-severe AD with involvement > 10% of body-surface-area (BSA) and investigator global assessment (IGA) score =3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits.
  • Subject has an Eczema Area and Severity Index (EASI) score =16 at screening and baseline.
  • Subject has a pruritus NRS =4.
  • Subject is biologic naïve.
  • Female subjects of (i.e., fertile, following menarche and until becoming unless permanently sterile) must agree either to commit to true abstinence throughout the study and for at least 17 weeks after the last study drug (SD) injection, when this is in line with the preferred and usual lifestyle of the subject, or to use a highly-effective and approved method of throughout the study and for at least 17 weeks after the last study drug injection.
  • Subject willing and able to comply with all of the clinical study protocol's time commitments and procedural requirements.
  • Understand and sign an form (ICF) (and assent form, when applicable) before any procedure(s) are performed.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with lebrikizumab or participation in a lebrikizumab study.
  • History of anaphylaxis as defined by the Sampson criteria.
  • Treatment with topical , calcineurin inhibitors, Jak inhibitors, or crisaborole within 1 week prior to the baseline visit.
  • Prior treatment with dupilumab or tralokinumab.
  • Treatment with any of the following agents within 4 weeks prior to the baseline visit:

    1. /immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-., Janus kinase inhibitors (JAKi), azathioprine, methotrexate).
    2. Phototherapy and photochemotherapy (PUVA) for AD.
  • Treatment with the following prior to the baseline visit:

    1. An drug within 8 weeks or 5 half-lives (if known), whichever is longer.
    2. Cell-depleting biologics, including to rituximab, within 6 months.
    3. Other biologics within 5 half-lives (if known) or 16 weeks, whichever is longer.
  • Use of prescription moisturizers within 7 days of the baseline visit.
  • Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the screening visit.
  • Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.
  • Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma requiring systemic [oral and/or parenteral] corticosteroid treatment or hospitalization for > 24 hours).
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, anti-parasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. NOTE: patients may be rescreened after infection resolves.
  • Evidence of active acute or chronic hepatitis (as defined by the Department of Health \& Human Services Centers for Disease Control and Prevention) or known liver cirrhosis.
  • Diagnosed active endoparasitic infections or at high risk of these infections.
  • Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis [TB], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment.
  • History of (HIV) infection or positive HIV serology at screening.
  • In the Investigator's opinion, any laboratory results from the chemistry, hematology or urinalysis tests available in the medical history.
  • Presence of skin comorbidities that may interfere with study assessments.
  • History of , including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin.
  • Severe concomitant illness(es) that in the Investigator's judgment would adversely affect the patient's participation in the study. Any other medical or psychological condition that in the opinion of the Investigator may suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study patient because of his/her participation in this clinical trial, may make patient's participation unreliable, or may interfere with study assessments.

    20. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Moderate-to-severe Atopic Dermatitis

    A total of 48 subjects with active moderate-to-severe Atopic Dermatitis (AD) will be enrolled in a 60-week study from 4 independent sites (2 US sites and 2 EU sites).

    Drug: lebrikizumab

Interventions

  • Patients will receive lebrikizumab with a 500 mg loading dose administered subcutaneously at baseline and Week 2 followed by 250 mg every 2 weeks until Week 24. At week 24, patients with ≥ Eczema Area and Severity Index (EASI) 50 will continue in the study and begin receiving lebrikizumab 250mg every 4 weeks (Q4W), while patients with \<EASI 50 will be discontinued from the study. At week 36, patients with EASI ≥50 to \<90 will remain on Q4W through W60 (do not enter withdrawal arm), while patients with sustained low disease activity (IGA 0/1 or EASI≥90 response for at least 3 months assessed at W24 and W36) will withdraw from lebrikizumab treatment

    Also known as: Ebglyss

06

What researchers measure

Primary outcomes

  1. Degree of normalization of transcriptomic/epigenetic profile

    Assessed from skin biopsies using the molecular response to lebrikizumab among patients with atopic dermatitis

    Time frame: Up to week 60

Secondary outcomes

  1. Molecular response to Lebrikizumab

    Assessed from skin biopsies using the molecular response to lebrikizumab among patients with atopic dermatitis, analyzed for those who discontinued treatment as well as those who continued it

    Time frame: weeks 36 to 60

  2. Skin barrier function

    Assessed by serial transepidermal water loss (TEWL) measurements in lesional skin. TEWL will be measured using Courage + Khazaka gmbh tewameter hex for spot measurements

    Time frame: Up to week 60

  3. Clinical response as assessed be the Eczema Area and Severity Index (EASI)

    Clinical response assessed using the EASI - Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicating greater severity of AD to be correlated with Molecular response, assessed using single-cell RNA-sequencing This will be done using correlation based analyses and with correction for multiple testing (FDR).

    Time frame: Up to week 60

  4. Clinical response as assessed using the investigator global assessment (IGA)

    Clinical response assessed using the IGA - Score ranges from '0' = Clear to '5' = Very Severe Disease to be correlated with molecular response, assessed using single-cell RNA-sequencing. This will be done using correlation based analyses and with correction for multiple testing (FDR).

    Time frame: Up to week 60

  5. Clinical response as assessed using the Peak Pruritus Numerical Rating Scale (NRS) (Pruitis NRS)

    Clinical response assessed using the Pruitis NRS - is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. That will be correlated with the molecular response, assessed using single-cell RNA-sequencing This will be done using correlation based analyses and with correction for multiple testing (FDR).

    Time frame: Up to week 60

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 2, 2025
StartActual
Jul 2, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06906497
Lead sponsor
Johann E Gudjonsson MD PhD
Responsible party
Johann E Gudjonsson MD PhD (Professor of Skin Molecular Immunology, Professor of Dermatology, Professor of Internal Medicine and Research Pr, University of Michigan) — Sponsor-investigator
First posted
Apr 2, 2025
Start date
Jul 2, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Johann E. Gudjonsson, MD, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion